Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update

Macitentan is a medication in the endothelin receptor antagonist class, approved for treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal SERAPHIN Trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome)....

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Alexandra K, Channick, Richard N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731963/
https://www.ncbi.nlm.nih.gov/pubmed/31564989
http://dx.doi.org/10.2147/DHPS.S173050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731963/
https://www.ncbi.nlm.nih.gov/pubmed/31564989
http://dx.doi.org/10.2147/DHPS.S173050

Ejemplares similares